SCHEMBL1906141

SCHEMBL1906141

Cc1cc(C#N)ccc1Nc1ccc(C(=NO)c2ccccc2C)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.51
MAPK13 O15264 10/20 0.51
MAPK12 P53778 10/20 0.51
MAPK11 Q15759 10/20 0.51
AR P10275 2/20 0.36
DHODH Q02127 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
AVPR2 P30518 1/20 0.35
GPR27 Q9NS67 1/20 0.35
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
SLC2A1 P11166 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1907990 0.85 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL5173645 0.85 MAPK14 (0.68) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL1908182 0.85 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11AR
SCHEMBL5172468 0.85 MAPK14 (0.72) MAPK14MAPK13MAPK12MAPK11AVPR2
SCHEMBL1908404 0.85 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL1906251 0.84 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL1905973 0.84 MAPK14 (0.72) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL1906645 0.82 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL1908390 0.80 MAPK14 (0.57) MAPK14MAPK13MAPK12MAPK11DHODH
SCHEMBL1907474 0.79 MAPK14 (0.59) MAPK14MAPK13MAPK12MAPK11DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4684515-B2 2011-05-18 JP claimed
US-6541670-B2 Antiinflammatory agents LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-04-01 US claimed
US-20030013770-A1 Aminobenzophenones as inhibitors of il 1b and tnf LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-01-16 US claimed
EP-1237845-A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 2002-09-11 EP claimed
WO-2001042189-A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-06-14 WO claimed
EP-1237845-B1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA LEO PHARMA AS (DK) 2007-05-23 EP disclosed
US-6541670-B2 Antiinflammatory agents LEO PHARMACEUTICAL PRODUCTS LTD. A/S (DK) 2003-04-01 US disclosed
EP-1237845-A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1BETA AND TNF-ALPHA LEO PHARMACEUTICAL PRODUCTS LTD. A/S (LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB) (DK) 2002-09-11 EP disclosed
WO-2001042189-A1 AMINOBENZOPHENONES AS INHIBITORS OF IL-1β AND TNF-$g(a) LEO PHARMA A/S (DK) 2001-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013770-A1 Aminobenzophenones as inhibitors of il 1b and tnf IL1B, IL1A, IL6 MAPK14 1553/4885MAPK13 2221/4885MAPK12 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.